Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity
Fig 2
Poor oral bioavailability of Tylosin A impairs clearance of Wolbachia endosymbionts in vivo.
A. Experimental design for L. sigmodontis larval mouse study. B. Worm lengths (an indicator of development) from L. sigmodontis larval mouse model; animals treated with doxycycline (200 mg/kg PO BID X 14 days) or TylA (200 mg/kg IP or PO, BID X 7 days) or vehicle control (VC). By simple non-parametric Mann-Whitney test: TylA IP against TylA PO and TylA vs vehicle are highly significant p<0.0001, TylA IP vs DOX control and vehicle vs TylA PO = ns C. Plasma levels of TylA in BALB/c mice following IP or PO dosing (100 mg/kg).